Related Experiment Video
Updated: Jun 14, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020
R Stephanie Huang1, M Eileen Dolan
1Department of Medicine, University of Chicago, IL 60637, USA.
Abstract:
Pharmacogenomics is emerging as an important component both in facilitating new drug development and in improving the utility of existing chemotherapeutic agents. Both candidate gene and genome-wide approaches have been used to identify genetic markers associated with chemotherapeutic response and/or toxicity. New molecular targeted agents have been designed based on a sophisticated understanding of the molecular alterations defining cancers. Over the next decade, the translation of these findings into clinical practice, as well as functional studies of genetic variants, is likely to take center stage. More comprehensive evaluation of the human genome, including the examination of rare SNPs, copy number variations, tandem repeats and epigenetic effects, will further improve our understanding of the relationship between genetics and drug response.
Insights
Pharmacogenomics is revolutionizing drug development and cancer treatment by identifying genetic markers for drug response and toxicity. Future research will integrate comprehensive genomic analysis for personalized medicine.
Area of Science:
- Pharmacogenomics
- Cancer Therapeutics
- Molecular Biology
Background:
- Pharmacogenomics plays a crucial role in advancing drug development and optimizing chemotherapy.
- Identifying genetic markers is key to predicting patient response and toxicity to chemotherapeutic agents.
Purpose of the Study:
- To highlight the growing importance of pharmacogenomics in drug development and clinical practice.
- To emphasize the need for comprehensive genomic evaluation for personalized medicine.
Main Methods:
- Utilizing candidate gene and genome-wide association studies to identify genetic markers.
- Designing molecular targeted agents based on cancer-specific molecular alterations.
Main Results:
- Pharmacogenomic approaches have identified genetic markers linked to chemotherapeutic outcomes.
- Molecularly targeted therapies are being developed using advanced understanding of cancer genetics.
Conclusions:
- Translating pharmacogenomic findings into clinical practice is a priority for the next decade.
- Further research into rare SNPs, copy number variations, tandem repeats, and epigenetics will deepen the understanding of pharmacogenomics.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Principles of Pharmacogenetics: Types of Genetic Variants
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
